Investigation to assess the efficacy of benzyl benzoate emulsion versus permethrin creme for scabies treatment

Investigation to assess the efficacy of topical benzyl benzoate 10/25% emulsion versus permethrin 5% creme for scabies treatment - Investigation of benzyl benzoate 25% emulsion versus permethrin 5% creme in scabies

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2022-000660-22-AT

Enrollment

100

Registered

2022-03-10

Start date

2022-06-14

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scabies

Interventions

Trade Name: Infectoscab 5% Creme Product Name: Infectoscab Product Code: P03AC04 Pharmaceutical Form: Cream INN or Proposed INN: Permethrin CAS Number: 52645-53-1 Current Sponsor code: n.a. Other desc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - diagnosis of scabies (dermatoscopically confirmed) - age =6 years Are the trial subjects under 18? yes Number of subjects for this age range: 100 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10

Exclusion criteria

Exclusion criteria: -Scabies crustosa - use of topical Permethrin (e.g. Infectoscab 5% Creme®) or Benzyl Benzoate emulsion or oral ivermectin within the last 3 weeks exception: childres 6-18 years and or adults with high mite density (>5 mites) can be included 2 weeks after pre-treatment. - allergy or intolerance agains top. benzyl benzoate emulsion or permethrin cream - mental disfunction - pregnancy/breast-feeding - alcohol abuse

Design outcomes

Primary

Measure	Time frame
Main Objective: topical Benzyl Benzoate ist superior to topical permethrin in treating scabies;Secondary Objective: n.a.;Primary end point(s): cure rate of topical benzyl benzoate versus topical permethrin in treating scabies;Timepoint(s) of evaluation of this end point: week 3 (to 5)	—

Secondary

Measure	Time frame
Secondary end point(s): safety and tolerability of of topical benzyl benzoate versus topical permethrin in treating scabies;Timepoint(s) of evaluation of this end point: week 3 (to 5);	—

Countries

Austria

Contacts

Public ContactUniversitätsklinik für Dermatologie

Landeskrankenhaus Salzburg

d.meyersburg@salk.at00435725558673

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026